Logo-ps
Pharm Sci. 2021;27(4): 568-574.
doi: 10.34172/PS.2021.5
  Abstract View: 222
  PDF Download: 114

Research Article

A Comparison on Effects of High Dose Rosuvastatin versus High Dose Atorvastatin on Lipid Profile and CRP Level in Patients Undergoing Percutaneous Coronary Intervention: A Randomized Study

Mahboubeh Darban 1 ORCID logo, Elham Yusefabadi 2, Majid Mirmohammad Khani 3,4, Bahram Sohrabi 5, Bahador Bagheri 6,7* ORCID logo

1 Department of Internal Medicine, Kowsar Hospital, Semnan University of Medical Sciences, Semnan, Iran.
2 Student Research Committee, Kowsar Hospital, Semnan University of Medical Sciences, Semnan, Iran.
3 Social Determinates of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran.
4 Department of Epidemiology and Biostatistics, Semnan University of Medical Sciences, Semnan, Iran.
5 Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
6 Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran.
7 Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.

Abstract

Background: Statins are the most common drugs used for reducing low-density lipids (LDL). In addition to their lipid-lowering effects, they have well-documented anti-inflammatory actions. The goal of this study was to compare the effects of high dose atorvastatin and rosuvastatin on lipid profiles and high sensitivity C Reactive Protein (hs-CRP) in patients undergoing percutaneous coronary intervention (PCI).

Methods: The study was done between October 2017 and September 2018 in Semnan KowsarHospital. In this randomized trial, 69 patients with atherosclerotic coronary artery disease were randomly assigned 1:1 to receive atorvastatin (80 mg daily) or rosuvastatin (40 mg daily) for4 months. Levels of hs-CRP and lipid profiles including cholesterol, triglyceride, low-density lipids (LDL), and high-density lipids (HDL) were measured and compared before and after the treatments. Lipid profiles were measured at baseline, 2 months, and 4 months of the treatment.

Results: Sixty patients completed the study. The mean age was 61.1 ± 6.6 years with an excess of males. After 4 months, both drugs could significantly reduce LDL levels, however, the between-group differences were not statistically significant. Rosuvastatin significantly increased HDL levels (p < 0.05). In addition, triglyceride levels had a significant reduction in both groups, yet the differences were not significant. Both drugs caused significant reductions in hs-CRP levels(p < 0.05). Moreover, the effects of treatments were seen in drug naïve patients as well as patients who were on statins prior to the trial.

Conclusion: The results indicate that high dose therapies with atorvastatin and rosuvastatin have similar effects on lipid profiles and hs-CRP levels in patients undergoing PCI.

Keywords: Rosuvastatin, Atherosclerosis, Atorvastatin, Lipid profile, hs-CRP
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 223

Your browser does not support the canvas element.


PDF Download: 114

Your browser does not support the canvas element.

Submitted: 14 Apr 2020
Revision: 21 Jan 2021
Accepted: 21 Jan 2021
ePublished: 03 Feb 2021
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)